logo

For the Inventor, By the Inventor

Dongguan, China

Sunshine Lake Pharma Co., Ltd.

Calculating rank
USPTO Granted Patents = 119

% Expired Patents = 7.6



Forward Citations = 300

Loading Chart...
Loading Chart...

224 inventors (with patents filed for the assignee):

goldMedal Yingjun Zhang (61 out of 64 patents)

silverMedal Ning Xi (27 out of 76 patents)

bronzeMedal Qingyun Ren (26 out of 27 patents)

4.  Siegfried Goldmann (16 out of 100 patents)

5.  Chuanfei Jin (13 out of 13 patents)

6.  Xiaojun Wang (13 out of 21 patents)

7.  Xinchang Liu (12 out of 12 patents)

8.  Jiancun Zhang (12 out of 13 patents)

9.  Zheng Gu (10 out of 11 patents)

10.  Yanjun Wu (9 out of 9 patents)

11.  Changhua Tang (8 out of 9 patents)

12.  Junjun Yin (7 out of 8 patents)

13.  Kai Yi (7 out of 8 patents)

14.  Bing Liu (7 out of 9 patents)

15.  Fangfang Huang (7 out of 8 patents)


Core Competencies:
Pharmaceuticals
RET Inhibitors
Influenza Virus
Tricyclic Compounds
Dihydropyrimidine
Glucopyranosyl Derivatives
Thienopyrimidine
Fused Compounds
Aromatic Heterocycles
Crystalline Forms
Piperazine Compounds
Antagonists

119 patents:

1. 12742012 - HUMANIZED ANTI-TRKA ANTIBODIES AND USES THEREOF (2026-09-22),
2. 12715846 - Crystal form of quinolinone compound and use thereof (2026-08-25),
3. 12662462 - Salts of pyridinylmethylenepiperidine derivatives and uses thereof (2026-06-23),
4. 12630507 - Pyrrolidine amide derivative salt and use thereof (2026-05-19),
5. 12617769 - Chemical compound as thyroid hormone beta receptor agonist and use thereof (2026-05-05),
6. 12590132 - FGF21 VARIANT POLYPEPTIDE MOLECULES AND APPLICATION THEREOF (2026-03-31),
7. 12558338 - Pharmaceutical composition (2026-02-24),
8. 12527763 - Pyrrole amide compound and use thereof (2026-01-20),
9. 12502387 - Lurasidone solid dispersion and preparation method thereof (2025-12-23),
10. 12492211 - Crystalline form of nitrogen-containing tricyclic compound and use thereof (2025-12-09),
11. 12435108 - Teixobactin analogue and use thereof (2025-10-07),
12. 12428432 - Thienopyrimidine derivatives having stereo configurations and use thereof in medicine (2025-09-30),
13. 12428389 - Diarylamide compound and application thereof (2025-09-30),
14. 12324812 - Glucopyranosyl derivatives and their uses (2025-06-10),
15. 12312348 - RET inhibitors, pharmaceutical compositions and uses thereof (2025-05-27),
Company Overview
Sunshine Lake Pharma Co., Ltd., headquartered in Dongguan, China, specializes in the development and manufacturing of pharmaceutical compounds. The company focuses on innovative therapeutic solutions, particularly in the realm of RET inhibitors and antiviral treatments targeting the influenza virus. Their research encompasses a range of advanced chemical compounds, including tricyclic compounds, dihydropyrimidine, glucopyranosyl derivatives, thienopyrimidine, and fused compounds, positioning them at the forefront of pharmaceutical innovation.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

119 Patents

#7 in Dongguan

#289 in China

#6,706 in the World

Dongguan, CN
Dongguan, China

Sunshine Lake Pharma Co., Ltd.

Forward Citations = 300

224 inventors:

goldMedal Yingjun Zhang (61 out of 64 patents)

silverMedal Ning Xi (27 out of 76 patents)

bronzeMedal Qingyun Ren (26 out of 27 patents)

4.  Siegfried Goldmann (16 out of 100 patents)

5.  Chuanfei Jin (13 out of 13 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Sunshine Lake Pharma Co., Ltd.. Retrieved from https://idiyas.com/company/sunshine-lake-pharma-company

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…